Abstract
Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Graphical Abstract
Current Vascular Pharmacology
Title:Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Volume: 16 Issue: 1
Author(s): Vassiliki Mamakou, Ioanna Eleftheriadou, Niki Katsiki, Konstantinos Makrilakis, Konstantinos Tsioufis and Nikolaos Tentolouris*
Affiliation:
- First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens,Greece
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Abstract: Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Export Options
About this article
Cite this article as:
Mamakou Vassiliki , Eleftheriadou Ioanna , Katsiki Niki , Makrilakis Konstantinos , Tsioufis Konstantinos and Tentolouris Nikolaos*, Antidiabetic Drugs as Antihypertensives: New Data on the Horizon, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666171010122332
DOI https://dx.doi.org/10.2174/1570161115666171010122332 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member:
Current Vascular Pharmacology Do Human Lipoxygenases have a PDZ Regulatory Domain?
Current Molecular Medicine Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema
Current Diabetes Reviews Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry Chronic Cerebral Hypoperfusion Protects Against Acute Focal Ischemia,Improves Motor Function, and Results in Vascular Remodeling
Current Neurovascular Research In Vivo Electroporation of Gene Sequences for Therapeutic and Vaccination Applications
Recent Patents on DNA & Gene Sequences Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients
Current HIV Research Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Novel High Throughput Polymer Biocompatibility Screening Designed for SAR (Structure-Activity Relationship): Application for Evaluating Polymer Coatings for Cardiovascular Drug-Eluting Stents
Combinatorial Chemistry & High Throughput Screening Current Status of Ethosomes and Elastic Liposomes in Dermal and Transdermal Drug Delivery
Current Pharmaceutical Design Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
Current Neurovascular Research Lipid Profile of Children Suffering from Pediatric Rheumatic Diseases (pRDS)
Current Rheumatology Reviews Beneficial Effects of N-acetylcysteine and N-mercaptopropionylglycine on Ischemia Reperfusion Injury in the Heart
Current Medicinal Chemistry Acute Toxicological and Histopathological Elucidation of <i>Rheum emodi</i> Rhizome Extract to Demonstrate Antidiabetic Activity in Alloxan-induced Diabetic Rats
Current Bioactive Compounds Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews The Role of Nitric oxide (NO) Donors in the Treatment of Male Infertility
Current Pharmaceutical Design Possible Predictive Value of Maspin Expression in Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery